

## **DIPROSONE LOTION**

### **(Betamethasone Dipropionate)**

#### **ABRIDGED PRESCRIBING INFORMATION**

Diprosone Lotion contains Betamethasone 0.05% as Dipropionate, a synthetic fluorinated corticosteroid.

**Uses:** Diprosone Lotion is indicated for eczema and dermatitis of all types affecting the scalp and also psoriasis of the scalp.

**Dosage:** A few drops should be applied to the affected area twice daily and massaged gently in.

**Contraindications:** Hypersensitivity to any of the ingredients, rosacea, acne, perioral dermatitis, perianal and genital pruritis. Tuberculous or viral lesions of skin, napkin eruptions, fungal or bacterial skin infections without suitable concomitant anti-infective therapy.

**Precautions and Warnings:** Long-term continuous therapy should be avoided in all patients and occlusion must not be used. Limit use on face or in children to 5 days. Use in psoriasis may result in rebound relapse due to tolerance, and risk of generalised pustular psoriasis or local systemic toxicity due to impaired barrier function of skin. Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression and manifestations of Cushing's syndrome. Infrequently, signs and symptoms of steroid withdrawal may occur on discontinuation. Not for ophthalmic use. Paediatric patients may be particularly susceptible to adrenal suppression due to a larger skin surface area to body weight ratio. Manifestations of intracranial hypertension have been reported.

**Pregnancy and Lactation:** Topical steroids should be used only if the potential benefit justifies the potential risk to the foetus or infant.

**Side-effects:** Common: Diprosone preparations are generally well tolerated and side effects are rare. Serious: Excessive prolonged use of topical corticosteroids can suppress the HPA axis. The Summary of product Characteristics (SmPC) should be consulted for further details.

**Pack size:** 30ml or 100ml. **Legal Category:** POM.

**NHS Price:** £2.73 (30ml); £7.80 (100ml).

**Marketing Authorisation Number:** PL 00025/0572.

**Marketing Authorisation Holder:** Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, UK.

**Please refer to the full SPC text before prescribing this product. Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk) (UK). Adverse events should also be reported to MSD Drug Safety Department on +44 (0)1707 363773.**

**Date of Revision of Text:** February 2011

*Diprosone-L/UK/API/02-11/4*